{"url_path":"/sec/cik-0001845459/8-k/2026-05-21/item-3-02","section_key":"item-3-02","section_title":"Item 3.02 Unregistered Sales of Equity Securities.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1845459/0001213900-26-060160-index.html","accession_number":"0001213900-26-060160","cik":"0001845459","ticker":null,"issuer_name":"NKGen Biotech, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1845459/0001213900-26-060160-index.html","primary_entity_key":"0001845459","primary_entity_name":"NKGen Biotech, Inc."},"word_count":161,"has_tables":true,"body_markdown":"**Item 3.02. Unregistered Sales of Equity Securities.**\n\n \n\nThe disclosures set forth in Item 1.01 are incorporated\ninto this Item 3.02 by reference.\n\n \n\nIn connection with the transactions described\nunder Item 1.01 above, on May 15, 2026, the Company agreed to issue to the Lender the following securities (the “Securities”)\nwithout registration under the Securities Act of 1933, as amended (the “Securities Act”):\n\n \n\n \n(a)\nThe Consideration Shares to be issued in five installments commencing on the five-month anniversary of the closing date of the Loan Agreement;\n\n \n\n \n(b)\nthe Additional Note #2, which is convertible into shares of Common Stock at a conversion price of $0.08 per share, subject to adjustment; and\n\n \n\n \n(c)\nthe Additional Warrant #2, which is exercisable for shares of Common Stock at an exercise price of $0.08 per share, subject to adjustment.\n\n \n\nThe Securities were issued and sold in reliance\nupon exemptions from registration requirements of the Securities Act, pursuant to Section 4(a)(2), Regulation D and/or Regulation S thereunder."}